https://www.tissuegene.com/en_US/product-pipeline
Product Pipeline :: Kolon TissueGene, Inc. (950160)
TissueGene, is developing four product candidates, InvossaTM (TG-C), TG-B, TG-D and TG-N for the regeneration of cartilage, bone, disc and nerve, respectively.
product pipelinekolon tissuegeneinc
https://www.tissuegene.com/en_US/about/history
History :: Kolon TissueGene, Inc. (950160)
TissueGene, Inc. is a clinical-stage bio-pharmaceutical company focused on developing novel regenerative therapies in the field of cell therapy.
kolon tissuegenehistoryinc
https://www.tissuegene.com/en_US/investors/analyst-report
Analyst Report :: Kolon TissueGene, Inc. (950160)
analyst reportkolon tissuegeneinc
https://www.tissuegene.com/en_US/product-pipeline/applications
Applications :: Kolon TissueGene, Inc. (950160)
kolon tissuegeneapplicationsinc
https://www.tissuegene.com/en_US/technology
Technology :: Kolon TissueGene, Inc. (950160)
TissueGene has developed a novel method for overcoming the challenges associated with therapeutic proteins by harnessing their regenerative capabilities.
kolon tissuegenetechnologyinc